ALFA FinderBSE filing, NSE: MACINTR. Summary written from the filing by ALFA Finder's alert engine.
Astal Laboratories Ltd: key numbers
- Share price
- ₹63.24
- Market cap
- ₹267.0 Cr
- Revenue (annual)
- ₹156.0 Cr
- Net profit (annual)
- ₹8.12 Cr
- P/E (TTM)
- 27.4×Sector 47.0×
- Promoter holding
- 4.59%+0.06% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Astal Laboratories Ltd
All →Astal Laboratories Q2 FY27 Results: Net Profit ₹3.8 Cr, Up 46.2% YoY
Astal Laboratories Ltd reported revenue from operations of ₹40.7 Cr (+8.5% YoY) and net profit of ₹3.8 Cr (+46.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹3.8 Cr · +46.2% YoY
Astal Laboratories Board Meeting Date
Astal Laboratories will hold a board meeting on 13 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The trading window stays closed until 48 hours after the meeting.
Astal Laboratories Other Announcement
Astal Laboratories submitted the Regulation 74(5) certificate from its Registrar for the quarter ended September 30, 2026, confirming the dematerialization activities.
Astal Laboratories Other Announcement
Astal Laboratories' material subsidiary, Sriven Pharmachem India, appointed new Internal, Cost, and Secretarial Auditors. The appointments were approved during the subsidiary's board meeting on September 28, 2026.
Astal Laboratories Management Change
Astal Laboratories Limited has appointed Ms. Ambika Kedia as Company Secretary of its material wholly-owned subsidiary, Sriven Pharmachem India Private Limited. The appointment is effective from September 28, 2026.
Astal Laboratories Annual General Meeting
Astal Laboratories held its 33rd Annual General Meeting on September 29, 2026. Members transacted business regarding financial statements and the re-appointment of a director.
Other other announcement announcements
All →Pennar Industries Other Announcement
Pennar's Reg 32 statement reports no deviation in preferential warrant proceeds for the quarter ended September 2026. This is routine periodic compliance with no new capital event.
Arshiya Other Announcement
Arshiya Ltd disclosed it cannot submit Q2 and H1 FY27 un-audited standalone and consolidated results due to CIRP, resolution professional control, and office relocation disruptions. The filing gives no new business event, only a delay explanation.
Deccan Gold Mines Other Announcement
Deccan Gold Mines filed a monitoring agency report for the quarter ended 30 September 2026 on its Rs 314.70 crore rights issue. The report shows no deviation from the issue objects.
CSM Technologies Other Announcement
CSM Technologies filed its IPO Monitoring Agency Report for the quarter ended September 30, 2026. The report shows no deviation from objects but flags fund co-mingling.
360 One Wam Other Announcement
Designated person Mayur Patel sold 61,365 equity shares of 360 ONE WAM via market sale between 6 and 11 November 2026. The sale value is Rs.7.05 Crore.
- Value
- ₹7.05 Cr
Aegeus Technologies Other Announcement
Aegeus Technologies filed CARE Ratings' monitoring agency report for the quarter ended September 30, 2026. It reports IPO proceeds utilised per stated objects, with no deviation.